Physician profile
Gregory Altimari
NPI 1952603052
$2,842.84
in general payments reported to CMS, 2019-2025
21 companies · $881 in 2025
The $881 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $401 · 2022: $384 · 2023: $358 · 2024: $820 · 2025: $881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,058.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $504.85 | 2021-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $355.24 | 2021-2025 | Jardiance |
| Pfizer INC. | $279.01 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $262.25 | 2021-2024 | Xarelto |
| Abbott Laboratories | $217.82 | 2023-2025 | Aveir, Amplatzer Amulet, Gallant |
| Boston Scientific Corporation | $212.66 | 2023-2025 | Watchman Access System, Emblem Mri S-Icd, Bodyguardian |
| Medtronic, INC. | $204.53 | 2021-2025 | Micra, Linq II |
| Actelion Pharmaceuticals US, INC. | $139.99 | 2024 | Uptravi, Opsumit |
| Abiomed | $125.02 | 2024 | Impella |
| Cvrx, INC. | $113.32 | 2025 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $107.95 | 2024-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $89.78 | 2021-2025 | Wainua, Farxiga |
| Merck Sharp & Dohme LLC | $42.05 | 2024 | Verquvo |
| Amgen INC. | $37.63 | 2025 | Repatha |
| Kiniksa Pharmaceuticals International, Plc | $28.75 | 2024 | Arcalyst |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $27.82 | 2021 | |
| Biotronik INC. | $20.56 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.48 | 2025 | |
| Novartis Pharmaceuticals Corporation | $18.64 | 2024 | |
| Amarin Pharma, INC. | $18.47 | 2021 | |
| Vital Connect, INC | $17.02 | 2023 | Vitalpatch Rtm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Altimari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.